COMMENTARY: Review: Thiazolidinediones increase risk for heart failure in type 2 diabetes

Byrne, Christopher D.
January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p5
Academic Journal
The author comments on the meta- analysis concerning the association of thiazolidinediones for heart failures in patients with non-insulin-dependent diabetes. He asserts that the study is useful for practicing health care professionals due to the magnitude of risk is quantified. He pointed out that the study recommends changes to package inserts for thiazolidinedione drugs. He suggests to define the precise role of thiazolidinediones in the management of type 2 diabetes in further studies.


Related Articles

  • Review: Thiazolidinediones increase risk for heart failure in type 2 diabetes.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p5 

    The article presents a clinical study that evaluates the risk for heart failure associated with thiazolidinediones in patients with non-insulin-dependent diabetes. The evaluation was conducted on patients with diabetes and heart failure of more than six months. A meta-analysis revealed that the...

  • Prevalence, Incidence and Risk Factors of Chronic Heart Failure in the Type 2 Diabetic Population: Systematic Review. Linuo Zhou; Wei Deng; Lixue Zhou; Ping Fang; Daikun He; Weiwei Zhang; Kui Liu; Renming Hu // Current Diabetes Reviews;2009, Vol. 5 Issue 3, p171 

    Objectives: The aim of this review was to examine the prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population. Methods: A systematic search of studies related to chronic heart failure (CHF) in the diabetic population was performed using medical...

  • What is the best first-line therapy for type 2 diabetes? Price, Hermione; Cavan, David // Diabetes Digest;2015, Vol. 14 Issue 3, p146 

    The article offers the author's insights as multidisciplinary team members on the published paper regarding the comparative effectiveness patient-centered study on the initial choice for diabetes mellitus oral glucose-lowering treatment. Topics mentioned include the effectiveness of first-line...

  • Effects of Thiazolidinediones Beyond Glycaemic Control. Kalaitzidis, Rigas G.; Sarafidis, Pantelis A.; Bakris, George L. // Current Pharmaceutical Design;2/11/2009, Vol. 15 Issue 5, p529 

    The incidence of type 2 diabetes continues to increase in the western world over the past decade. Consequently, complications of this disease have reached crisis proportions. In addition to the classical oral hypoglycaemic agents, i.e. sulfonylureas, newer classes have emerged that work by...

  • Thiazolidinediones and Cardiovascular Risk -- A Question of Balance. Erdmann, Erland; Charbonnel, Bernard; Wilcox, Robert // Current Cardiology Reviews;2009, Vol. 5 Issue 3, p155 

    Background: Several recent meta-analyses of adverse event data from randomized controlled trials with rosiglitazone reveal a possible association between this thiazolidinedione and an increased risk of ischemic myocardial events. This has led to debate on the overall clinical benefit of...

  • in the clinic: Heart Failure. Goldberg, Lee R. // Annals of Internal Medicine;6/1/2010, Vol. 152 Issue 11, pITC6-1 

    The article focuses on the prevention, diagnosis, and treatment of heart failure. It discusses risk factors including hypertension and type 2 diabetes mellitus, medications for the prevention of heart failure, the symptoms of heart failure, treatment options and recommendations from professional...

  • 2007 - Thiazolidinediones increased risk for heart failure, myocardial infarction, and death in older patients with type 2 diabetes. Padwal, Raj // ACP Journal Club;6/20/2008, Vol. 148 Issue 4, p12 

    The article discusses whether thiazolidinediones (TZDs) increase risk for heart failure (HF), myocardial infarction (MI), and mortality more than other oral hypoglycemic agents in older patients with type 2 diabetes. Nested case-control study in a retrospective cohort study with a median...

  • Type 2 diabetes therapies may increase HF risk.  // Formulary;May2005, Vol. 40 Issue 5, p166 

    Discusses a study which found that the use of any pharmacological therapy for type 2 diabetes appears to be associated with an increased risk of heart failure. Indication that the risk does not extend beyond the first year after diagnosis and does not appear to differ among the types of drug...

  • Insulin For Type 2 Diabetes: Who, When, And Why? Tanenberg, Robert // Diabetes Health;Dec2007/Jan2008, Vol. 16 Issue 6, p34 

    The article discusses the indicators of when to use insulin in type 2 diabetes melitus. Conditions that may render oral anti diabetic drugs ineffective and necessitates insulin administration include serious illnesses, pregnancy, major surgery, congestive heart failure, kidney and liver...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics